SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Beresford MW, Baildam EM.New advances in the management of juvenile idiopathic arthritis–2: the era of biologicals.Arch Dis Child Educ Pract Ed2009;94:1516.
  • 2
    Braun J, Sieper J.Biological therapies in the spondyloarthritides: the current state.Rheumatology (Oxford)2004;43:107284.
  • 3
    Olsen NJ, Stein CM.New drugs for rheumatoid arthritis.N Engl J Med2004;350:216779.
  • 4
    Karampetsou MP, Liossis SN, Sfikakis PP.TNF-α antagonists beyond approved indications: stories of success and prospects for the future.QJM2010;103:91728.
  • 5
    Perez-Zafrilla B, Carmona L, Gomez-Reino JJ.Infections in patients with rheumatic diseases treated with TNF antagonists.Curr Pharm Biotechnol2012;13:141825.
  • 6
    Chakravarty EF, Michaud K, Wolfe F.Skin cancer, rheumatoid arthritis, and tumor necrosis factor inhibitors.J Rheumatol2005;32:21305.
  • 7
    Sfikakis PP, Iliopoulos A, Elezoglou A, Kittas C, Stratigos A.Psoriasis induced by anti–tumor necrosis factor therapy: a paradoxical adverse reaction.Arthritis Rheum2005;52:25138.
  • 8
    Harrison MJ, Dixon WG, Watson KD, King Y, Groves R, Hyrich KL, et al.Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor α therapy: results from the British Society for Rheumatology Biologics Register.Ann Rheum Dis2009;68:20915.
  • 9
    Hernandez MV, Nogues S, Ruiz-Esquide V, Alsina M, Canete JD, Sanmarti R.Development of alopecia areata after biological therapy with TNF-α blockers: description of a case and review of the literature.Clin Exp Rheumatol2009;27:8923.
  • 10
    Hernandez MV, Ruiz-Esquide V, Gomez-Caballero ME, Gomez-Puerta JA, Canete JD, Sanmarti R.Relapsing polychondritis: a new adverse event secondary to the use of tumour necrosis factor antagonists?Rheumatology (Oxford)2011;50:15235.
  • 11
    Ramirez J, Hernandez MV, Galve J, Canete JD, Sanmarti R.Morphea associated with the use of adalimumab: a case report and review of the literature.Mod Rheumatol2012;22:6024.
  • 12
    Ramirez-Hernandez M, Marras C, Martinez-Escribano JA.Infliximab-induced vitiligo [letter].Dermatology2005;210:7980.
  • 13
    Carmona L, Descalzo MA, Ruiz-Montesinos D, Manero-Ruiz FJ, Perez-Pampin E, Gomez-Reino JJ, et al.Safety and retention rate of off-label uses of TNF antagonists in rheumatic conditions: data from the Spanish registry BIOBADASER 2.0.Rheumatology (Oxford)2011;50:8592.
  • 14
    Keystone EC, Kavanaugh AF, Sharp JT, Tannenbaum H, Hua Y, Teoh LS, et al.Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti–tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial.Arthritis Rheum2004;50:140011.
  • 15
    Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macfarlane JD, et al.Therapeutic efficacy of multiple intravenous infusions of anti–tumor necrosis factor α monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis.Arthritis Rheum1998;41:155263.
  • 16
    Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI, et al.A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate.N Engl J Med1999;340:2539.
  • 17
    Bonnet N, Guis S, Koeppel MC, Roudier J, Grimaud JC, Jean-Pastor MJ, et al.Cutaneous events during anti-TNF α therapy: a prospective observational study of 41 cases.Ann Dermatol Venereol2010;137:1220. In French.
  • 18
    Exarchou SA, Voulgari PV, Markatseli TE, Zioga A, Drosos AA.Immune-mediated skin lesions in patients treated with anti-tumour necrosis factor α inhibitors.Scand J Rheumatol2009;38:32831.
  • 19
    Flendrie M, Vissers WH, Creemers MC, de Jong EM, van de Kerkhof PC, van Riel PL.Dermatological conditions during TNF-α-blocking therapy in patients with rheumatoid arthritis: a prospective study.Arthritis Res Ther2005;7:R66676.
  • 20
    Lee HH, Song IH, Friedrich M, Gauliard A, Detert J, Rowert J, et al.Cutaneous side-effects in patients with rheumatic diseases during application of tumour necrosis factor-α antagonists.Br J Dermatol2007;156:48691.
  • 21
    Garcia-Doval I, Perez-Zafrilla B, Descalzo MA, Rosello R, Hernandez MV, Gomez-Reino JJ, et al.Incidence and risk of hospitalisation due to shingles and chickenpox in patients with rheumatic diseases treated with TNF antagonists.Ann Rheum Dis2010;69:17515.
  • 22
    Strangfeld A, Listing J, Herzer P, Liebhaber A, Rockwitz K, Richter C, et al.Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-α agents.JAMA2009;301:73744.
  • 23
    Galloway JB, Mercer LK, Moseley A, Dixon WG, Ustianowski AP, Helbert M, et al.Risk of skin and soft tissue infections (including shingles) in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register.Ann Rheum Dis2013;72:22934.
  • 24
    Dixon WG, Watson K, Lunt M, Hyrich KL, British Society for Rheumatology Biologics Register Control Centre Consortium,Silman AJ, et al, on behalf of the British Society for Rheumatology Biologics Register.Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti–tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register.Arthritis Rheum2006;54:236876.
  • 25
    Listing J, Strangfeld A, Kary S, Rau R, von Hinueber U, Stoyanova-Scholz M, et al.Infections in patients with rheumatoid arthritis treated with biologic agents.Arthritis Rheum2005;52:340312.
  • 26
    Winthrop KL, Baddley JW, Chen L, Liu L, Grijalva CG, Delzell E, et al.Association between the initiation of anti-tumor necrosis factor therapy and the risk of herpes zoster.JAMA2013;309:88795.
  • 27
    Salliot C, Gossec L, Ruyssen-Witrand A, Luc M, Duclos M, Guignard S, et al.Infections during tumour necrosis factor-α blocker therapy for rheumatic diseases in daily practice: a systematic retrospective study of 709 patients.Rheumatology (Oxford)2007;46:32734.
  • 28
    Ansel J, Perry P, Brown J, Damm D, Phan T, Hart C, et al.Cytokine modulation of keratinocyte cytokines.J Invest Dermatol1990;94 Suppl:101S7S.
  • 29
    Metz M, Maurer M.Innate immunity and allergy in the skin.Curr Opin Immunol2009;21:68793.
  • 30
    Wollina U, Hansel G, Koch A, Schonlebe J, Kostler E, Haroske G.Tumor necrosis factor-α inhibitor-induced psoriasis or psoriasiform exanthemata: first 120 cases from the literature including a series of six new patients.Am J Clin Dermatol2008;9:114.
  • 31
    Collamer AN, Battafarano DF.Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: clinical features and possible immunopathogenesis.Semin Arthritis Rheum2010;40:23340.
  • 32
    Ettefagh L, Nedorost S, Mirmirani P.Alopecia areata in a patient using infliximab: new insights into the role of tumor necrosis factor on human hair follicles [letter].Arch Dermatol2004;140:1012.
  • 33
    Pelivani N, Hassan AS, Braathen LR, Hunger RE, Yawalkar N.Alopecia areata universalis elicited during treatment with adalimumab.Dermatology2008;216:3203.
  • 34
    Williams VL, Cohen PR.TNF α antagonist-induced lupus-like syndrome: report and review of the literature with implications for treatment with alternative TNF α antagonists.Int J Dermatol2011;50:61925.
  • 35
    Pontikaki I, Shahi E, Frasin LA, Gianotti R, Gelmetti C, Gerloni V, et al.Skin manifestations induced by TNF-α inhibitors in juvenile idiopathic arthritis.Clin Rev Allergy Immunol2012;42:1314.
  • 36
    Mattozzi C, Richetta AG, Cantisani C, Giancristoforo S, D'Epiro S, Gonzalez Serva A, et al.Morphea, an unusual side effect of anti-TNF-α treatment [letter].Eur J Dermatol2010;20:4001.
  • 37
    Voulgari PV, Markatseli TE, Exarchou SA, Zioga A, Drosos AA.Granuloma annulare induced by anti-tumour necrosis factor therapy.Ann Rheum Dis2008;67:56770.
  • 38
    Carmona L, Abasolo L, Descalzo MA, Perez-Zafrilla B, Sellas A, de Abajo F, et al.Cancer in patients with rheumatic diseases exposed to TNF antagonists.Semin Arthritis Rheum2011;41:7180.
  • 39
    Dixon WG, Carmona L, Finckh A, Hetland ML, Kvien TK, Landewe R, et al.EULAR points to consider when establishing, analysing and reporting safety data of biologics registers in rheumatology.Ann Rheum Dis2010;69:1596602.
  • 40
    Wolfe F, Michaud K.Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study.Arthritis Rheum2007;56:288695.
  • 41
    Askling J, Fored CM, Brandt L, Baecklund E, Bertilsson L, Feltelius N, et al.Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists.Ann Rheum Dis2005;64:14216.
  • 42
    Mariette X, Matucci-Cerinic M, Pavelka K, Taylor P, van Vollenhoven R, Heatley R, et al.Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis.Ann Rheum Dis2011;70:1895904.
  • 43
    Mariette X, Reynolds AV, Emery P.Updated meta-analysis of non-melanoma skin cancer rates reported from prospective observational studies in patients treated with tumour necrosis factor inhibitors.Ann Rheum Dis2012;71:e2.
  • 44
    Chuang TY, Brashear R.Risk factors of non-melanoma skin cancer in United States veterans patients: a pilot study and review of literature.J Eur Acad Dermatol Venereol1999;12:12632.
  • 45
    Douglas KM, Ladoyanni E, Treharne GJ, Hale ED, Erb N, Kitas GD.Cutaneous abnormalities in rheumatoid arthritis compared with non-inflammatory rheumatic conditions.Ann Rheum Dis2006;65:13415.
  • 46
    Mercer LK, Green AC, Galloway JB, Davies R, Lunt M, Dixon WG, et al.The influence of anti-TNF therapy upon incidence of keratinocyte skin cancer in patients with rheumatoid arthritis: longitudinal results from the British Society for Rheumatology Biologics Register.Ann Rheum Dis2012;71:86974.
  • 47
    Widdifield J, Bernatsky S, Paterson JM, Gunraj N, Thorne JC, Pope J, et al.Serious infections in a population-based cohort of 86,039 seniors with rheumatoid arthritis.Arthritis Care Res (Hoboken)2013;65:35361.
  • 48
    McDonough AK, Curtis JR, Saag KG.The epidemiology of glucocorticoid-associated adverse events.Curr Opin Rheumatol2008;20:1317.
  • 49
    Smolen JS, Kalden JR, Scott DL, Rozman B, Kvien TK, Larsen A, et al, and the European Leflunomide Study Group.Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial.Lancet1999;353:25966.
  • 50
    Kalden JR, Antoni C, Alvaro-Gracia JM, Combe B, Emery P, Kremer JM, et al.Use of combination of leflunomide with biological agents in treatment of rheumatoid arthritis.J Rheumatol2005;32:162031.